share_log

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

2022年9月15日的重要生物技術催化劑-當天結束摘要
Benzinga Real-time News ·  2022/09/15 18:48
Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7 to $46.29 on day volume of 15.14 million shares, closed regular trading session at $45.94.
輝瑞公司(紐約證券交易所股票代碼:PFE)宣佈了關鍵的第三階段試驗的正面結果,該試驗評估了其正在研究的五價腦膜炎雙球菌疫苗(MenABCWY)在10至25歲健康人羣中的安全性、耐受性和免疫原性。試驗滿足了所有主要和次要終端。輝瑞股價在45.7美元至46.29美元的區間內交易,當日成交量為1,514萬股,常規交易時段收於45.94美元。
Alnylam (NASDAQ: ALNY) and Regeneron (NASDAQ: REGN) announced preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis (NASH). Alnylam shares traded in a range of $202.6 to...
阿爾尼拉姆(納斯達克:ALNY)和再生納斯達克代碼:REGN)宣佈了支持ALN-...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論